{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T12:14:08Z","timestamp":1782562448319,"version":"3.54.5"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,5,15]],"date-time":"2021-05-15T00:00:00Z","timestamp":1621036800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,5,15]],"date-time":"2021-05-15T00:00:00Z","timestamp":1621036800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Little is known about the safety and efficacy of concurrent capecitabine and stereotactic radiotherapy in the setting of breast cancer brain metastases (BCBM).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Twenty-three patients with BCBM underwent 31 stereotactic sessions to 90 lesions from 2005 to 2019 with receipt of capecitabine. The Kaplan-Meier method was used to calculate overall survival (OS), local control (LC), and distant intracranial control (DIC) from the date of stereotactic radiation. Imaging was independently reviewed by a neuro-radiologist.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Median follow-up from stereotactic radiation was 9.2\u2009months. Receptor types of patients treated included triple negative (<jats:italic>n<\/jats:italic>\u2009=\u20097), hormone receptor (HR)+\/HER2- (<jats:italic>n<\/jats:italic>\u2009=\u20097), HR+\/HER2+ (<jats:italic>n<\/jats:italic>\u2009=\u20096), and HR\u2212\/HER2+ (<jats:italic>n<\/jats:italic>\u2009=\u20093). Fourteen patients had stage IV disease prior to BCBM diagnosis. The median number of brain metastases treated per patient was 3 (1 to 12). The median dose of stereotactic radiosurgery (SRS) was 21\u2009Gy (range: 15\u201324\u2009Gy) treated in a single fraction and for lesions treated with fractionated stereotactic radiation therapy (FSRT) 25\u2009Gy (24\u201330\u2009Gy) in a median of 5 fractions (range: 3\u20135). Of the 31 stereotactic sessions, 71% occurred within 1\u2009month of capecitabine. No increased toxicity was noted in our series with no cases of radionecrosis. The 1-year OS, LC, and DIC were 46, 88, and 30%, respectively.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>In our single institution experience, we demonstrate stereotactic radiation and capecitabine to be a safe treatment for patients with BCBM with adequate LC. Further study is needed to determine the potential synergy between stereotactic radiation and capecitabine in the management of BCBM.<\/jats:p><\/jats:sec>","DOI":"10.1186\/s12885-021-08302-9","type":"journal-article","created":{"date-parts":[[2021,5,15]],"date-time":"2021-05-15T18:02:51Z","timestamp":1621101771000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Capecitabine and stereotactic radiation in the management of breast cancer brain metastases"],"prefix":"10.1186","volume":"21","author":[{"given":"Matthew N.","family":"Mills","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Afrin","family":"Naz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chetna","family":"Thawani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chelsea","family":"Walker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas B.","family":"Figura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergiy","family":"Kushchayev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel E.","family":"Oliver","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnold B.","family":"Etame","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hsiang-Hsuan Michael","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy J.","family":"Robinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James K. C.","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael A.","family":"Vogelbaum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter A.","family":"Forsyth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian J.","family":"Czerniecki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hatem H.","family":"Soliman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyo S.","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kamran A.","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,5,15]]},"reference":[{"issue":"2","key":"8302_CR1","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1007\/s10549-020-05552-2","volume":"180","author":"MN Mills","year":"2020","unstructured":"Mills MN, Figura NB, Arrington JA, Yu HM, Etame AB, Vogelbaum MA, et al. Management of brain metastases in breast cancer: a review of current practices and emerging treatments. Breast Cancer Res Treat. 2020;180(2):279\u2013300. https:\/\/doi.org\/10.1007\/s10549-020-05552-2.","journal-title":"Breast Cancer Res Treat"},{"issue":"36","key":"8302_CR2","doi-asserted-by":"publisher","first-page":"5658","DOI":"10.1200\/JCO.2006.07.0250","volume":"24","author":"Z Gabos","year":"2006","unstructured":"Gabos Z, Sinha R, Hanson J, Chauhan N, Hugh J, Mackey JR, et al. Prognostic significance of human epidermal growth factor receptor positivity for the development of brain metastasis after newly diagnosed breast cancer. J Clin Oncol. 2006;24(36):5658\u201363. https:\/\/doi.org\/10.1200\/JCO.2006.07.0250.","journal-title":"J Clin Oncol"},{"issue":"16","key":"8302_CR3","doi-asserted-by":"publisher","first-page":"2792","DOI":"10.1016\/j.ejca.2009.06.027","volume":"45","author":"F Heitz","year":"2009","unstructured":"Heitz F, Harter P, Lueck HJ, Fissler-Eckhoff A, Lorenz-Salehi F, Scheil-Bertram S, et al. Triple-negative and HER2-overexpressing breast cancers exhibit an elevated risk and an earlier occurrence of cerebral metastases. Eur J Cancer. 2009;45(16):2792\u20138. https:\/\/doi.org\/10.1016\/j.ejca.2009.06.027.","journal-title":"Eur J Cancer"},{"issue":"9","key":"8302_CR4","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1097\/01.pas.0000213306.05811.b9","volume":"30","author":"DG Hicks","year":"2006","unstructured":"Hicks DG, Short SM, Prescott NL, Tarr SM, Coleman KA, Yoder BJ, et al. Breast cancers with brain metastases are more likely to be estrogen receptor negative, express the basal cytokeratin CK5\/6, and overexpress HER2 or EGFR. Am J Surg Pathol. 2006;30(9):1097\u2013104. https:\/\/doi.org\/10.1097\/01.pas.0000213306.05811.b9.","journal-title":"Am J Surg Pathol"},{"issue":"2","key":"8302_CR5","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1093\/neuonc\/nou141","volume":"17","author":"A Morikawa","year":"2015","unstructured":"Morikawa A, Peereboom DM, Thorsheim HR, Samala R, Balyan R, Murphy CG, et al. Capecitabine and lapatinib uptake in surgically resected brain metastases from metastatic breast cancer patients: a prospective study. Neuro-Oncology. 2015;17(2):289\u201395. https:\/\/doi.org\/10.1093\/neuonc\/nou141.","journal-title":"Neuro-Oncology"},{"issue":"1","key":"8302_CR6","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/S1470-2045(12)70432-1","volume":"14","author":"T Bachelot","year":"2013","unstructured":"Bachelot T, Romieu G, Campone M, Dieras V, Cropet C, Dalenc F, et al. Lapatinib plus capecitabine in patients with previously untreated brain metastases from HER2-positive metastatic breast cancer (LANDSCAPE): a single-group phase 2 study. Lancet Oncol. 2013;14(1):64\u201371. https:\/\/doi.org\/10.1016\/S1470-2045(12)70432-1.","journal-title":"Lancet Oncol"},{"issue":"13","key":"8302_CR7","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1200\/JCO.18.01511","volume":"37","author":"RA Freedman","year":"2019","unstructured":"Freedman RA, Gelman RS, Anders CK, Melisko ME, Parsons HA, Cropp AM, et al. TBCRC 022: a phase II trial of Neratinib and Capecitabine for patients with human epidermal growth factor receptor 2-positive breast Cancer and brain metastases. J Clin Oncol. 2019;37(13):1081\u20139. https:\/\/doi.org\/10.1200\/JCO.18.01511.","journal-title":"J Clin Oncol"},{"issue":"22","key":"8302_CR8","doi-asserted-by":"publisher","first-page":"2147","DOI":"10.1056\/NEJMoa1612645","volume":"376","author":"N Masuda","year":"2017","unstructured":"Masuda N, Lee SJ, Ohtani S, Im YH, Lee ES, Yokota I, et al. Adjuvant Capecitabine for breast Cancer after preoperative chemotherapy. N Engl J Med. 2017;376(22):2147\u201359. https:\/\/doi.org\/10.1056\/NEJMoa1612645.","journal-title":"N Engl J Med"},{"issue":"5","key":"8302_CR9","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1245\/s10434-011-1630-6","volume":"18","author":"WF Regine","year":"2011","unstructured":"Regine WF, Winter KA, Abrams R, Safran H, Hoffman JP, Konski A, et al. Fluorouracil-based chemoradiation with either gemcitabine or fluorouracil chemotherapy after resection of pancreatic adenocarcinoma: 5-year analysis of the U.S. intergroup\/RTOG 9704 phase III trial. Ann Surg Oncol. 2011;18(5):1319\u201326. https:\/\/doi.org\/10.1245\/s10434-011-1630-6.","journal-title":"Ann Surg Oncol"},{"key":"8302_CR10","doi-asserted-by":"crossref","unstructured":"Allegra CJ, Yothers G, O'Connell MJ, Beart RW, Wozniak TF, Pitot HC, et al. Neoadjuvant 5-FU or Capecitabine Plus Radiation With or Without Oxaliplatin in Rectal Cancer Patients: A Phase III Randomized Clinical Trial. J Natl Cancer Inst. 2015;107(11). PMID: 26374429.","DOI":"10.1093\/jnci\/djv248"},{"issue":"1","key":"8302_CR11","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.ijrobp.2012.09.023","volume":"86","author":"LA Kachnic","year":"2013","unstructured":"Kachnic LA, Winter K, Myerson RJ, Goodyear MD, Willins J, Esthappan J, et al. RTOG 0529: a phase 2 evaluation of dose-painted intensity modulated radiation therapy in combination with 5-fluorouracil and mitomycin-C for the reduction of acute morbidity in carcinoma of the anal canal. Int J Radiat Oncol Biol Phys. 2013;86(1):27\u201333. https:\/\/doi.org\/10.1016\/j.ijrobp.2012.09.023.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"2","key":"8302_CR12","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1016\/S0360-3016(99)00507-6","volume":"47","author":"E Shaw","year":"2000","unstructured":"Shaw E, Scott C, Souhami L, Dinapoli R, Kline R, Loeffler J, et al. Single dose radiosurgical treatment of recurrent previously irradiated primary brain tumors and brain metastases: final report of RTOG protocol 90-05. Int J Radiat Oncol Biol Phys. 2000;47(2):291\u20138. https:\/\/doi.org\/10.1016\/S0360-3016(99)00507-6.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"8302_CR13","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1186\/s12885-021-07971-w","volume":"21","author":"MN Mills","year":"2021","unstructured":"Mills MN, Walker C, Thawani C, Naz A, Figura NB, Kushchayev S, et al. Trastuzumab Emtansine (T-DM1) and stereotactic radiation in the management of HER2+ breast cancer brain metastases. BMC Cancer. 2021;21(1):223. https:\/\/doi.org\/10.1186\/s12885-021-07971-w.","journal-title":"BMC Cancer"},{"issue":"3","key":"8302_CR14","first-page":"E685","volume":"108","author":"MN Mills","year":"2020","unstructured":"Mills MN, Naz A, Thawani C, Walker C, Figura NB, Forsyth P, et al. Clinical outcomes of breast Cancer brain metastases treated with stereotactic radiation and Capecitabine. IJROBP. 2020;108(3):E685\u20136.","journal-title":"IJROBP"},{"issue":"6","key":"8302_CR15","doi-asserted-by":"publisher","first-page":"e270","DOI":"10.1016\/S1470-2045(15)70057-4","volume":"16","author":"NU Lin","year":"2015","unstructured":"Lin NU, Lee EQ, Aoyama H, Barani IJ, Barboriak DP, Baumert BG, et al. Response assessment criteria for brain metastases: proposal from the RANO group. Lancet Oncol. 2015;16(6):e270\u20138. https:\/\/doi.org\/10.1016\/S1470-2045(15)70057-4.","journal-title":"Lancet Oncol"},{"issue":"4","key":"8302_CR16","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1007\/s002800050043","volume":"45","author":"J Schuller","year":"2000","unstructured":"Schuller J, Cassidy J, Dumont E, Roos B, Durston S, Banken L, et al. Preferential activation of capecitabine in tumor following oral administration to colorectal cancer patients. Cancer Chemother Pharmacol. 2000;45(4):291\u20137. https:\/\/doi.org\/10.1007\/s002800050043.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"9","key":"8302_CR17","first-page":"1297","volume":"14","author":"RL Schilsky","year":"2000","unstructured":"Schilsky RL. Pharmacology and clinical status of capecitabine. Oncology (Williston Park, NY). 2000;14(9):1297\u2013306 discussion 1309-1211.","journal-title":"Oncology (Williston Park, NY)"},{"issue":"10","key":"8302_CR18","first-page":"2948","volume":"5","author":"N Sawada","year":"1999","unstructured":"Sawada N, Ishikawa T, Sekiguchi F, Tanaka Y, Ishitsuka H. X-ray irradiation induces thymidine phosphorylase and enhances the efficacy of capecitabine (Xeloda) in human cancer xenografts. Clin Cancer Res. 1999;5(10):2948\u201353.","journal-title":"Clin Cancer Res"},{"issue":"5","key":"8302_CR19","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.1200\/JCO.1999.17.5.1339","volume":"17","author":"CW Whitney","year":"1999","unstructured":"Whitney CW, Sause W, Bundy BN, Malfetano JH, Hannigan EV, Fowler WC Jr, et al. Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stage IIB-IVA carcinoma of the cervix with negative Para-aortic lymph nodes: a gynecologic oncology group and southwest oncology group study. J Clin Oncol. 1999;17(5):1339\u201348. https:\/\/doi.org\/10.1200\/JCO.1999.17.5.1339.","journal-title":"J Clin Oncol"},{"issue":"1","key":"8302_CR20","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1200\/JCO.2003.01.008","volume":"21","author":"DJ Adelstein","year":"2003","unstructured":"Adelstein DJ, Li Y, Adams GL, Wagner H Jr, Kish JA, Ensley JF, et al. An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer. J Clin Oncol. 2003;21(1):92\u20138. https:\/\/doi.org\/10.1200\/JCO.2003.01.008.","journal-title":"J Clin Oncol"},{"issue":"7","key":"8302_CR21","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1056\/NEJMoa1914609","volume":"382","author":"RK Murthy","year":"2020","unstructured":"Murthy RK, Loi S, Okines A, Paplomata E, Hamilton E, Hurvitz SA, et al. Tucatinib, Trastuzumab, and Capecitabine for HER2-positive metastatic breast Cancer. N Engl J Med. 2020;382(7):597\u2013609. https:\/\/doi.org\/10.1056\/NEJMoa1914609.","journal-title":"N Engl J Med"},{"issue":"21","key":"8302_CR22","doi-asserted-by":"publisher","first-page":"2483","DOI":"10.1001\/jama.295.21.2483","volume":"295","author":"H Aoyama","year":"2006","unstructured":"Aoyama H, Shirato H, Tago M, Nakagawa K, Toyoda T, Hatano K, et al. Stereotactic radiosurgery plus whole-brain radiation therapy vs stereotactic radiosurgery alone for treatment of brain metastases: a randomized controlled trial. JAMA. 2006;295(21):2483\u201391. https:\/\/doi.org\/10.1001\/jama.295.21.2483.","journal-title":"JAMA"},{"key":"8302_CR23","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/1748-717X-6-48","volume":"6","author":"G Minniti","year":"2011","unstructured":"Minniti G, Clarke E, Lanzetta G, Osti MF, Trasimeni G, Bozzao A, et al. Stereotactic radiosurgery for brain metastases: analysis of outcome and risk of brain radionecrosis. Radiat Oncol. 2011;6:48.","journal-title":"Radiat Oncol"},{"issue":"8","key":"8302_CR24","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1001\/jamaoncol.2017.3993","volume":"4","author":"AM Martin","year":"2018","unstructured":"Martin AM, Cagney DN, Catalano PJ, Alexander BM, Redig AJ, Schoenfeld JD, et al. Immunotherapy and symptomatic radiation necrosis in patients with brain metastases treated with stereotactic radiation. JAMA Oncol. 2018;4(8):1123\u20134. https:\/\/doi.org\/10.1001\/jamaoncol.2017.3993.","journal-title":"JAMA Oncol"},{"issue":"12","key":"8302_CR25","doi-asserted-by":"publisher","first-page":"2288","DOI":"10.1093\/annonc\/mdw417","volume":"27","author":"KA Ahmed","year":"2016","unstructured":"Ahmed KA, Abuodeh YA, Echevarria MI, Arrington JA, Stallworth DG, Hogue C, et al. Clinical outcomes of melanoma brain metastases treated with stereotactic radiosurgery and anti-PD-1 therapy, anti-CTLA-4 therapy, BRAF\/MEK inhibitors, BRAF inhibitor, or conventional chemotherapy. Ann Oncol. 2016;27(12):2288\u201394. https:\/\/doi.org\/10.1093\/annonc\/mdw417.","journal-title":"Ann Oncol"},{"issue":"2","key":"8302_CR26","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1007\/s11060-017-2437-5","volume":"133","author":"KA Ahmed","year":"2017","unstructured":"Ahmed KA, Kim S, Arrington J, Naghavi AO, Dilling TJ, Creelan BC, et al. Outcomes targeting the PD-1\/PD-L1 axis in conjunction with stereotactic radiation for patients with non-small cell lung cancer brain metastases. J Neuro-Oncol. 2017;133(2):331\u20138. https:\/\/doi.org\/10.1007\/s11060-017-2437-5.","journal-title":"J Neuro-Oncol"},{"issue":"1","key":"8302_CR27","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.ijrobp.2017.05.028","volume":"99","author":"NL Williams","year":"2017","unstructured":"Williams NL, Wuthrick EJ, Kim H, Palmer JD, Garg S, Eldredge-Hindy H, et al. Phase 1 study of Ipilimumab combined with whole brain radiation therapy or radiosurgery for melanoma patients with brain metastases. Int J Radiat Oncol Biol Phys. 2017;99(1):22\u201330. https:\/\/doi.org\/10.1016\/j.ijrobp.2017.05.028.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"4","key":"8302_CR28","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1016\/j.jtho.2018.01.012","volume":"13","author":"HG Hubbeling","year":"2018","unstructured":"Hubbeling HG, Schapira EF, Horick NK, Goodwin KEH, Lin JJ, Oh KS, et al. Safety of combined PD-1 pathway inhibition and intracranial radiation therapy in non-small cell lung Cancer. J Thorac Oncol. 2018;13(4):550\u20138. https:\/\/doi.org\/10.1016\/j.jtho.2018.01.012.","journal-title":"J Thorac Oncol"},{"issue":"4","key":"8302_CR29","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1097\/CMR.0000000000000268","volume":"26","author":"KR Patel","year":"2016","unstructured":"Patel KR, Chowdhary M, Switchenko JM, Kudchadkar R, Lawson DH, Cassidy RJ, et al. BRAF inhibitor and stereotactic radiosurgery is associated with an increased risk of radiation necrosis. Melanoma Res. 2016;26(4):387\u201394. https:\/\/doi.org\/10.1097\/CMR.0000000000000268.","journal-title":"Melanoma Res"},{"issue":"1","key":"8302_CR30","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1007\/s11060-014-1685-x","volume":"122","author":"KA Ahmed","year":"2015","unstructured":"Ahmed KA, Freilich JM, Sloot S, Figura N, Gibney GT, Weber JS, et al. LINAC-based stereotactic radiosurgery to the brain with concurrent vemurafenib for melanoma metastases. J Neuro-Oncol. 2015;122(1):121\u20136. https:\/\/doi.org\/10.1007\/s11060-014-1685-x.","journal-title":"J Neuro-Oncol"},{"issue":"18","key":"8302_CR31","doi-asserted-by":"publisher","first-page":"4127","DOI":"10.1200\/JCO.2005.07.144","volume":"23","author":"Y Cao","year":"2005","unstructured":"Cao Y, Tsien CI, Shen Z, Tatro DS, Ten Haken R, Kessler ML, et al. Use of magnetic resonance imaging to assess blood-brain\/blood-glioma barrier opening during conformal radiotherapy. J Clin Oncol. 2005;23(18):4127\u201336. https:\/\/doi.org\/10.1200\/JCO.2005.07.144.","journal-title":"J Clin Oncol"},{"issue":"12","key":"8302_CR32","doi-asserted-by":"publisher","first-page":"1601","DOI":"10.1093\/neuonc\/now137","volume":"18","author":"G Appelboom","year":"2016","unstructured":"Appelboom G, Detappe A, LoPresti M, Kunjachan S, Mitrasinovic S, Goldman S, et al. Stereotactic modulation of blood-brain barrier permeability to enhance drug delivery. Neuro-oncology. 2016;18(12):1601\u20139. https:\/\/doi.org\/10.1093\/neuonc\/now137.","journal-title":"Neuro-oncology"},{"issue":"1","key":"8302_CR33","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.radonc.2017.08.006","volume":"125","author":"F Teng","year":"2017","unstructured":"Teng F, Tsien CI, Lawrence TS, Cao Y. Blood-tumor barrier opening changes in brain metastases from pre to one-month post radiation therapy. Radiother Oncol. 2017;125(1):89\u201393. https:\/\/doi.org\/10.1016\/j.radonc.2017.08.006.","journal-title":"Radiother Oncol"},{"issue":"3","key":"8302_CR34","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1007\/s11060-008-9791-2","volume":"93","author":"C Chargari","year":"2009","unstructured":"Chargari C, Kirova YM, Dieras V, Castro Pena P, Campana F, Cottu PH, et al. Concurrent capecitabine and whole-brain radiotherapy for treatment of brain metastases in breast cancer patients. J Neuro-Oncol. 2009;93(3):379\u201384. https:\/\/doi.org\/10.1007\/s11060-008-9791-2.","journal-title":"J Neuro-Oncol"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-021-08302-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-021-08302-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-021-08302-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,27]],"date-time":"2022-12-27T13:26:53Z","timestamp":1672147613000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-021-08302-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,15]]},"references-count":34,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["8302"],"URL":"https:\/\/doi.org\/10.1186\/s12885-021-08302-9","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,15]]},"assertion":[{"value":"8 March 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 April 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 May 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The University of South Florida Institutional Review Board (ID Pro00023399) approved the present study. The need for consent to participate was waived by the University of South Florida Institutional Review Board, as the present study was a retrospective protocol that utilized anonymized data. Permission to access the data was approved by the University of South Florida Institutional Review Board.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Hyo S. Han declares that she has received a speaker\u2019s honorarium from Lilly Pharmaceuticals, research funding from Abbvie, Tesaro, TapImmune, Novartis, Bristol-Myers Squibb, Pfizer, SeattleGenetics, Prescient, Horizon, and Karyopharm. Peter A. Forsyth has received research funding from Pfizer and Celgene and is on the advisory boards of Novocure, BTG, Inovio, AbbVie, Ziopharm, Tocagen, and Pfizer. Kamran A. Ahmed has received research funding from Bristol-Myers Squibb and Genentech. Michael A. Vogelbaum has indirect equity and royalty interests in Infuseon Therapeutics, Inc. and has received honoraria from Tocagen, Inc. and Celgene. Hatem Soliman serves as a consultant for Astrazeneca, Celgene, Novartis, PUMA, and Eisai. Brian J Czerniecki has intellectual property on a HER2 dendritic cell vaccine. Hsiang-Hsuan Michael Yu has received spearker\u2019s honoraria from BrainLab and is on the advisory boards of Novocure and Abbvie.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"552"}}